These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28815894)

  • 41. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies.
    Berg AT; Ludwig NN; Wojnaroski M; Chapman CAT; Hommer R; Conecker G; Hecker JZ; Downs J
    Neurology; 2024 Jan; 102(1):e207958. PubMed ID: 38165374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
    Morant AV; Jagalski V; Vestergaard HT
    Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient.
    Winter E; Schliebner S
    Curr Rev Clin Exp Pharmacol; 2022; 17(1):39-45. PubMed ID: 33726656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical research for rare disease: opportunities, challenges, and solutions.
    Griggs RC; Batshaw M; Dunkle M; Gopal-Srivastava R; Kaye E; Krischer J; Nguyen T; Paulus K; Merkel PA;
    Mol Genet Metab; 2009 Jan; 96(1):20-6. PubMed ID: 19013090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rare diseases research: expanding collaborative translational research opportunities.
    Groft SC
    Chest; 2013 Jul; 144(1):16-23. PubMed ID: 23880676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?
    Rath A; Salamon V; Peixoto S; Hivert V; Laville M; Segrestin B; Neugebauer EAM; Eikermann M; Bertele V; Garattini S; Wetterslev J; Banzi R; Jakobsen JC; Djurisic S; Kubiak C; Demotes-Mainard J; Gluud C
    Trials; 2017 Nov; 18(1):556. PubMed ID: 29166947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases.
    Miller KL; Miller Needleman KI
    Contemp Clin Trials; 2023 Jun; 129():107198. PubMed ID: 37068589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The need for worldwide policy and action plans for rare diseases.
    Forman J; Taruscio D; Llera VA; Barrera LA; Coté TR; Edfjäll C; Gavhed D; Haffner ME; Nishimura Y; Posada M; Tambuyzer E; Groft SC; Henter JI;
    Acta Paediatr; 2012 Aug; 101(8):805-7. PubMed ID: 22519914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Therapeutic Uses for Existing Drugs.
    Austin BA; Gadhia AD
    Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.